Lv1
40 积分 2023-11-15 加入
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2个月前
已完结
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
2个月前
已完结
MOONRISE-1: PHASE 3 STUDY OF TAR-210, AN ERDAFITINIB INTRAVESICAL TARGETED RELEASING SYSTEM, VERSUS INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH FGFR-ALTERED INTERMEDIATE-RISK NON–MUSCLE-INVASIVE BLADDER CANCER
3个月前
已关闭
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
4个月前
已完结
Advances and challenges in targeting FGFR signalling in cancer
4个月前
已完结
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies
4个月前
已完结
The evolving genomic landscape of urothelial carcinoma
4个月前
已完结
Fibroblast growth factor receptors as treatment targets in clinical oncology
4个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
4个月前
已完结
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia
5个月前
已完结
皖公网安备34019202002308
